[Clinical course of patient with malignant pheochromocytoma who was treated with CVD chemotherapy and alpha-methyl-p-tyrosine].
A 31-years-old woman was diagnosed as pheocromocytoma by the various endocrine testings and 131I-MIBG scintigraphy. The CT scan and bone scintigraphy showed right adrenal tumor, along with liver metastasis, lymph nodes swelling around aorta and multiple bone metastases. She underwent chemotherapy consisting with Cyclophosphamide, Vincristine, Dacarbazine (CVD) and alpha-methyl-p-tyrosine (alphaMT), resulting in stable disease for 27 months. However, catecholamine levels increased gradually four weeks later. We would have planned 131I-MIBG therapy, but bone marrow suppression did not allow us to do it. She died of DIC.
Nagata
Masao
M
Hamamatsu University School of Medicine.
Takayama
Tatsuya
T
Nishijima
Nariaki
N
Mugiya
Soichi
S
Ushiyama
Tomomi
T
Ozono
Seiichiro
S
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003952:Diagnostic Imaging; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D010673:Pheochromocytoma / Q000175:diagnosis / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage; D019805:alpha-Methyltyrosine / Q000008:administration & dosage*
D004791:Enzyme Inhibitors; D014750:Vincristine; D019805:alpha-Methyltyrosine; D003606:Dacarbazine; D003520:Cyclophosphamide